Newbury Pharmaceuticals
enters the Nordics with exciting
product portfolio

We are rapidly growing hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

We are the local champion and alternative partner to the multinationals. We strive to have a positive impact in the society, bring products and technology that contribute to the overall healthcare system and patient’s wellbeing

Our culture is built around deep knowledge, openness and curiosity. We work hard but also know that life-work balance is key for success.

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in Scandinavia.

Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology.


Lars Minor

Lars Minor

CEO - Year of Employment 2021

Lars’ has long experience in the pharma industry and his previous position was Corporate Vice President for strategy and execution at LEO Pharma.

Fredrik Hellqvist

Fredrik Hellqvist

VP Sales & Marketing - Year of Employment 2021

Fredrik has a long successful career in the pharma industry and his previous position was member of the leadership team of Abbvie Scandinavia as well as Business Unit Director of Scandinavia.

Christoffer Tell

Christoffer Tell

CFO - Year started 2021

Christoffer started his career as an auditor and later continued as CFO within multiple industries included two companies listed at Nasdaq First North in Sweden.

Karl Karlsson

Karl Karlsson

Founder & Executive Chairman - Year of Employment 2020

20 years experience as an entrepreneur, implementing growth strategy and rapid market expansion and his previous position was founder, President & CEO and Board Member of Bluefish Pharmaceuticals.

Portfolio Strategy

Newbury has built a strong portfolio with a total of 30 products. Newbury’s existing portfolio is focused on the Scandinavian market with an annual sales value of approximately EUR 800 million.

The portfolio consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology representing more than 70 percent.

The existing product portfolio will ensure a steady stream of product launches in the coming years. In addition, Newbury has a strong focus on expanding its portfolio of strategically important products.
Person Icon
Our culture is built around deep knowlegde, openness and curiosity
House Icon
Your local champion and alternative partner
Heart Icon
We strive to have a positive impact in the society